Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
Phase 2
Terminated
NCT04163432
| Condition | Non-Small Cell Lung Cancer Metastatic |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | University of Utah |
|---|
| Status | Terminated |
|---|
| Enrollment | 43 participants |
|---|
| Interventions | Durvalumab, Pemetrexed, Carboplatin |
|---|
| Start date | Jun 18, 2020 |
|---|
| Completion date | May 24, 2025 |
|---|
| Results posted | May 19, 2026 |
|---|
Summary
This is a Phase II, open label, randomized study of durvalumab in combination with pemetrexed and carboplatin in eligible adult patients with locally advanced or metastatic non-small cell lung cancer. The study will focus on the efficacy of two alternative staggered dosing regimens.
Clinical Benefit
up to 11 months from the start of study treatment · Participants
| Arm A: Chemo-Immuno | 17 Participants |
|---|
| Arm B: Immuno-Chemo | 13 Participants |
|---|
| Arm A: Chemo-Immuno | 4 Participants |
|---|
| Arm B: Immuno-Chemo | 9 Participants |
|---|
| Arm A: Chemo-Immuno | 14 Participants |
|---|
| Arm B: Immuno-Chemo | 11 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.